CGD09 V3
Homo sapiens
Protocols: IFN-γ administration was initiated at the dose of 50 mcg/m2 given subcutaneously on the standard schedule of Monday, Wednesday, and Friday in the evening before bedtime. Then, 10-12 hours after the 1st dose, and the 4th dose of IFN-γ additional blood samples were obtained. Neutrophils were isolated from heparinized peripheral blood by Dextran sedimentation, Ficoll-Hypaque density centrifugation, and hypotonic lysis of red blood cells 36,37. Neutrophils were quantitated manually in a hemocytometer in the presence of 3% paraformaldehyde. RNA from neutrophils was isolated by standard technique. RNA was used to prepare libraries using the Universal Plus mRNA-seq kit from Tecan Genomics (Redwood City, CA).
ENA first public
2024-07-01
External Id
SAMEA115057847
INSDC center name
Bioinformatic Solutions LLC
INSDC last update
2023-12-22T14:19:24Z
INSDC status
public
Submitter Id
E-MTAB-13674:CGD09 V3
age
13.4 YO
broker name
ArrayExpress
cell_type
neutrophils
collection date
not collected
common name
human
compound
IFNG
developmental stage
juvenile
disease
chronic granulomatous disease
dose
50
dosing time
Blood draw 10-12 hours after the 1st dose
geographic location (country and/or sea)
not collected
individual
CGD09
isolate
not applicable
organism part
blood
sample name
E-MTAB-13674:CGD09 V3
scientific_name
Homo sapiens
sex
male